Eritoran is a Toll-like receptor 4 (TLR4) antagonist that presents a promising therapeutic approach to addressing the severe complications associated with MVD and other forms of septic shock, particularly those induced by Gram-negative bacteria, which is currently being tested in a phase 3 clinical trial enrolling patients with severe sepsis (ClinicalTrials.gov identifier: NCT00334828) [82,83,84]. This evidence concerns the gene TLR4 and Sepsis.